ONTX logo

Onconova Therapeutics (ONTX) EBITDA

Annual EBITDA

-$20.28 M
-$655.00 K-3.34%

December 31, 2023

Summary

Performance

1-Year Change

-3.34%

3-Year Change

+18.81%

5-Year Change

+12.68%

15-Year Change

+20.92%

ONTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$16.48 M

3-Year Low

-$20.28 M
ONTX annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ONTX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
ONTX next annual earnings announcement has not yet been scheduled

OtherONTXprofitabilitymetrics:

Annual Revenue

$226.00 K
ONTX annual revenue is $226.00 thousand

Annual Net Income

-$18.95 M
ONTX annual net profit is -$18.95 million

Annual EBIT

-$20.30 M
ONTX annual earnings before interest & taxes is -$20.30 million

Annual EPS

-$0.90
ONTX annual earnings per share is -$0.90

Quarterly EBITDA

-$5.21 M
-$750.00 K-16.82%

March 31, 2024

Summary

Performance

3-Month Change

-16.82%

1-Year Change

-16.82%

3-Year Change

-16.82%

5-Year Change

-16.82%

ONTX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$7.00 M
ONTX quarterly EBITDA is currently -174.43% below its historical high of $7.00 million

3-Year Low

-$6.13 M

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2024
ONTX previous earnings announcement was published on Mar 31, 2024

Next Quarterly Earnings Report Date

N/A
ONTX next earnings announcement has not yet been scheduled

OtherONTXprofitabilitymetrics:

Quarterly Revenue

$56.00 K
ONTX quarterly revenue is $56.00 thousand

Quarterly Net Income

-$4.98 M
ONTX quarterly net profit is -$4.98 million

Quarterly EBIT

-$5.21 M
ONTX quarterly earnings before interest & taxes is -$5.21 million

Quarterly EPS

-$0.24
ONTX quarterly earnings per share is -$0.24

TTM EBITDA

-$19.36 M
+$926.00 K+4.57%

March 31, 2024

Summary

Performance

3-Month Change

+4.57%

1-Year Change

+4.57%

3-Year Change

+4.57%

5-Year Change

+4.57%

ONTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$10.70 M

3-Year Low

-$22.11 M

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2024
ONTX previous earnings announcement was published on Mar 31, 2024

Next Quarterly Earnings Report Date

N/A
ONTX next earnings announcement has not yet been scheduled

OtherONTXprofitabilitymetrics:

TTM Revenue

$226.00 K
ONTX TTM revenue is $226.00 thousand

TTM Net Income

-$18.16 M
ONTX TTM net profit is -$18.16 million

TTM EBIT

-$19.37 M
ONTX TTM earnings before interest & taxes is -$19.37 million

TTM EPS

-$0.67
ONTX TTM earnings per share is -$0.67

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$20.28 M
ONTX annual EBITDA is -$20.28 million

Annual Net Income

-$18.95 M
ONTX annual net profit is -$18.95 million

Annual Interest Expense

-
ONTX annual interest expense value is unknown

Annual Income Tax

-
ONTX annual income tax value is unknown

Annual D&A

$16.00 K
ONTX annual depreciation & amortization is $16.00 thousand

ONTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-3.3%-16.8%+4.6%
3 y3 years+18.8%-16.8%+4.6%
5 y5 years+12.7%-16.8%+4.6%

ONTX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+23.1%at low+38.5%+17.8%+21.0%+14.2%
5 y5-year+23.1%+23.2%+38.5%+40.9%+21.0%+29.1%
alltimeall time+23.1%+212.1%-174.4%+283.7%+80.9%+259.5%

Onconova Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Mar 2024
-
-$5.21 M(+16.8%)
-$19.36 M(-4.6%)
Dec 2023
-$20.28 M(+3.3%)
-$4.46 M(-12.3%)
-$20.28 M(-5.9%)
Sep 2023
-
-$5.08 M(+10.4%)
-$21.55 M(-2.5%)
Jun 2023
-
-$4.61 M(-24.9%)
-$22.11 M(+2.3%)
Mar 2023
-
-$6.13 M(+7.1%)
-$21.62 M(+10.2%)
Dec 2022
-$19.63 M(+19.1%)
-$5.73 M(+1.6%)
-$19.61 M(+11.2%)
Sep 2022
-
-$5.64 M(+37.0%)
-$17.64 M(+10.3%)
Jun 2022
-
-$4.12 M(-0.3%)
-$15.99 M(-3.2%)
Mar 2022
-
-$4.13 M(+9.8%)
-$16.52 M(+0.2%)
Dec 2021
-$16.48 M(-34.0%)
-$3.76 M(-5.7%)
-$16.48 M(-13.1%)
Sep 2021
-
-$3.99 M(-14.1%)
-$18.97 M(-10.7%)
Jun 2021
-
-$4.64 M(+13.3%)
-$21.26 M(-11.3%)
Mar 2021
-
-$4.09 M(-34.5%)
-$23.95 M(-4.1%)
Dec 2020
-$24.98 M(+15.2%)
-$6.25 M(-0.3%)
-$24.98 M(+2.2%)
Sep 2020
-
-$6.27 M(-14.5%)
-$24.45 M(+5.0%)
Jun 2020
-
-$7.34 M(+43.2%)
-$23.28 M(+18.9%)
Mar 2020
-
-$5.12 M(-10.5%)
-$19.57 M(-9.7%)
Dec 2019
-$21.68 M(-6.6%)
-$5.72 M(+12.4%)
-$21.69 M(-1.9%)
Sep 2019
-
-$5.09 M(+40.2%)
-$22.10 M(-2.1%)
Jun 2019
-
-$3.63 M(-49.8%)
-$22.58 M(-8.1%)
Mar 2019
-
-$7.23 M(+17.9%)
-$24.57 M(+5.8%)
Dec 2018
-$23.23 M(-9.4%)
-$6.14 M(+10.0%)
-$23.23 M(+0.2%)
Sep 2018
-
-$5.58 M(-0.8%)
-$23.19 M(-4.8%)
Jun 2018
-
-$5.63 M(-4.4%)
-$24.35 M(-1.7%)
Mar 2018
-
-$5.89 M(-3.5%)
-$24.77 M(-3.4%)
DateAnnualQuarterlyTTM
Dec 2017
-$25.65 M(+8.6%)
-$6.10 M(-9.5%)
-$25.65 M(-1.3%)
Sep 2017
-
-$6.74 M(+11.4%)
-$26.00 M(+10.4%)
Jun 2017
-
-$6.04 M(-10.7%)
-$23.55 M(+2.9%)
Mar 2017
-
-$6.77 M(+5.0%)
-$22.88 M(-3.1%)
Dec 2016
-$23.61 M(-0.9%)
-$6.45 M(+50.2%)
-$23.61 M(+69.5%)
Sep 2016
-
-$4.29 M(-20.2%)
-$13.93 M(-10.1%)
Jun 2016
-
-$5.38 M(-28.3%)
-$15.48 M(-18.7%)
Mar 2016
-
-$7.50 M(-331.6%)
-$19.04 M(-20.1%)
Dec 2015
-$23.82 M(-62.4%)
$3.24 M(-155.3%)
-$23.82 M(-40.9%)
Sep 2015
-
-$5.85 M(-34.5%)
-$40.32 M(-18.2%)
Jun 2015
-
-$8.93 M(-27.3%)
-$49.26 M(-13.6%)
Mar 2015
-
-$12.28 M(-7.4%)
-$56.99 M(-10.0%)
Dec 2014
-$63.31 M(+2.7%)
-$13.26 M(-10.3%)
-$63.31 M(-1.7%)
Sep 2014
-
-$14.79 M(-11.3%)
-$64.38 M(-7.5%)
Jun 2014
-
-$16.67 M(-10.4%)
-$69.58 M(+6.4%)
Mar 2014
-
-$18.59 M(+29.7%)
-$65.38 M(+6.0%)
Dec 2013
-$61.67 M(+193.9%)
-$14.33 M(-28.3%)
-$61.67 M(+7.2%)
Sep 2013
-
-$19.98 M(+60.3%)
-$57.51 M(+88.4%)
Jun 2013
-
-$12.46 M(-16.3%)
-$30.53 M(+21.3%)
Mar 2013
-
-$14.89 M(+46.3%)
-$25.17 M(+20.0%)
Dec 2012
-$20.98 M(-19.2%)
-$10.18 M(-245.4%)
-$20.98 M(+94.1%)
Sep 2012
-
$7.00 M(-198.4%)
-$10.81 M(-39.3%)
Jun 2012
-
-$7.11 M(-33.6%)
-$17.81 M(+66.4%)
Mar 2012
-
-$10.70 M
-$10.70 M
Dec 2011
-$25.96 M
-
-

FAQ

  • What is Onconova Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Onconova Therapeutics?
  • What is Onconova Therapeutics annual EBITDA year-on-year change?
  • What is Onconova Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Onconova Therapeutics?
  • What is Onconova Therapeutics quarterly EBITDA year-on-year change?
  • What is Onconova Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Onconova Therapeutics?
  • What is Onconova Therapeutics TTM EBITDA year-on-year change?

What is Onconova Therapeutics annual EBITDA?

The current annual EBITDA of ONTX is -$20.28 M

What is the all time high annual EBITDA for Onconova Therapeutics?

Onconova Therapeutics all-time high annual EBITDA is -$16.48 M

What is Onconova Therapeutics annual EBITDA year-on-year change?

Over the past year, ONTX annual EBITDA has changed by -$655.00 K (-3.34%)

What is Onconova Therapeutics quarterly EBITDA?

The current quarterly EBITDA of ONTX is -$5.21 M

What is the all time high quarterly EBITDA for Onconova Therapeutics?

Onconova Therapeutics all-time high quarterly EBITDA is $7.00 M

What is Onconova Therapeutics quarterly EBITDA year-on-year change?

Over the past year, ONTX quarterly EBITDA has changed by -$750.00 K (-16.82%)

What is Onconova Therapeutics TTM EBITDA?

The current TTM EBITDA of ONTX is -$19.36 M

What is the all time high TTM EBITDA for Onconova Therapeutics?

Onconova Therapeutics all-time high TTM EBITDA is -$10.70 M

What is Onconova Therapeutics TTM EBITDA year-on-year change?

Over the past year, ONTX TTM EBITDA has changed by +$926.00 K (+4.57%)